Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer

Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC).

(2017) Y. Ou et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases.

(2017) Chris Parker et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial.

(2017) John C. Araujo et al.   JOURNAL OF CLINICAL ONCOLOGY

Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE).

(2017) Ian Tannock et al.   JOURNAL OF CLINICAL ONCOLOGY

Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways

(2013) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trials With Docetaxel-Based Combinations for Metastatic Castration-Resistant Prostate Cancer: Time to Learn From Past Experiences

(2013) Emmanuel S. Antonarakis et al.   JOURNAL OF CLINICAL ONCOLOGY

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

(2013) C. Parker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of Rash With Outcomes in a Randomized Phase II Trial Evaluating Cetuximab in Combination With Mitoxantrone Plus Prednisone After Docetaxel for Metastatic Castration-resistant Prostate Cancer

(2012) Mark T. Fleming et al.   Clinical Genitourinary Cancer

Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401

(2012) William Kevin Kelly et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

FGF Receptor Inhibitors: Role in Cancer Therapy

(2012) Gennaro Daniele et al.   Current Oncology Reports

c-Src and IL-6 inhibit osteoblast differentiation and integrate IGFBP5 signalling

(2012) Barbara Peruzzi et al.   Nature Communications

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer

(2011) Caterina Peraldo-Neia et al.   BMC CANCER

Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients

(2011) G Bousquet et al.   BRITISH JOURNAL OF CANCER

Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer

(2011) K Armstrong et al.   BRITISH JOURNAL OF CANCER

Dasatinib combined with docetaxel for castration-resistant prostate cancer

(2011) John C. Araujo et al.   CANCER

Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer

(2011) Brett S. Carver et al.   CANCER CELL

EGFR- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies

(2011) V. Poindessous et al.   CLINICAL CANCER RESEARCH

End Points and Outcomes in Castration-Resistant Prostate Cancer: From Clinical Trials to Clinical Practice

(2011) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Integrative Genomic Profiling of Human Prostate Cancer

(2010) Barry S. Taylor et al.   CANCER CELL

Prostate cancer incidence and mortality trends in 37 European countries: An overview

(2010) F. Bray et al.   EUROPEAN JOURNAL OF CANCER

Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

(2010) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study

(2010) Howard I Scher et al.   LANCET

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases

(2010) Y Liu et al.   ONCOGENE

Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer

(2009) Jeanny B. Aragon-Ching et al.   BJU INTERNATIONAL

Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth

(2009) A M Traish et al.   BRITISH JOURNAL OF CANCER

Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors

(2009) K. Mross et al.   CLINICAL CANCER RESEARCH

Src Family Kinase Activity Is Up-Regulated in Hormone-Refractory Prostate Cancer

(2009) O. Tatarov et al.   CLINICAL CANCER RESEARCH

BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy

(2008) F. Hilberg et al.   CANCER RESEARCH

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

(2008) D Li et al.   ONCOGENE

Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells

(2008) M Asim et al.   ONCOGENE